Stockscreener 앱 받기
5.07
5.41%
0.26
시간 외 거래:
5.04
-0.03
-0.59%
전일 마감가:
$4.81
열려 있는:
$4.998
하루 거래량:
2.81M
Relative Volume:
0.95
시가총액:
$859.04M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-253.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
-12.28%
1개월 성능:
-10.58%
6개월 성능:
+141.43%
1년 성능:
+676.65%
1일 변동 폭
$4.8201
$5.12
1주일 범위
$4.80
$5.74
52주 변동 폭
$0.40
$6.35
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
5.07 | 814.98M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Kynam Capital files 5.29% stake in CytomX (NASDAQ: CTMX) - Stock Titan
CytomX Therapeutics Target of Unusually High Options Trading (NASDAQ:CTMX) - MarketBeat
CytomX Therapeutics, Inc. to Announce Full Year 2025 Financial Results on March 16, 2026 - Quiver Quantitative
Biotech CytomX sets Mar. 16 call on 2025 financial results - Stock Titan
CTMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CytomX Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
CytomX Therapeutics, Inc. (CTMX): Investor Outlook Reveals 55.71% Potential Upside - DirectorsTalk Interviews
CTMXCytomx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Earnings Recap: Is CytomX Therapeutics Inc a good ESG investment2025 Stock Rankings & Proven Capital Preservation Methods - baoquankhu1.vn
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Will CytomX Therapeutics Inc. (6C1) stock rise with strong economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Unmasking CytomXA Pioneer In Masked Therapeutics - RTTNews
Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating - Finviz
Tang Capital reports 0% CytomX (CTMX) stake in latest 13G/A filing - Stock Titan
Is CytomX Therapeutics Inc. stock positioned well for digital economyDip Buying & Real-Time Buy Signal Notifications - mfd.ru
CTMX Should I Buy - Intellectia AI
Is CytomX Therapeutics Inc. (6C1) stock a fit for income portfolios2025 Buyback Activity & Expert Curated Trade Setups - mfd.ru
Will CytomX Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Big Picture & Entry Point Strategy Guides - mfd.ru
Can CytomX Therapeutics Inc. disrupt its industryEarnings Recap Summary & Fast Entry Momentum Alerts - mfd.ru
Market Trends: What hedge funds are buying CytomX Therapeutics Inc2025 Fundamental Recap & AI Enhanced Trading Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: Is CytomX Therapeutics Inc benefiting from interest rate changesMarket Sentiment Report & Technical Pattern Based Buy Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: A Biotech Pioneer with a 61.87% Potential Upside - DirectorsTalk Interviews
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts - MarketBeat
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares - GuruFocus
CytomX at Guggenheim Summit: Promising CRC Treatment Path By Investing.com - Investing.com Canada
Stock Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2025 Institutional Moves & Capital Protection Trade Alerts - baoquankhu1.vn
How New Analyst Assumptions Are Rewriting The Story For CytomX Therapeutics (CTMX) - Yahoo Finance
CTMX: Masked ADC shows 28% response in late-line CRC; registrational study planned by 2027 - TradingView
Rally Mode: Can CytomX Therapeutics Inc navigate macro headwindsJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
CytomX Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX) - The Globe and Mail
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: Exploring a 58.73% Potential Upside Amid Innovative Oncology Developments - DirectorsTalk Interviews
Analysis Recap: Whats the profit margin of CytomX Therapeutics IncWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Will CytomX Therapeutics Inc. (6C1) stock outperform foreign stocksJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - mfd.ru
CytomX Therapeutics (CTMX) Price Target Increased by 20.20% to 8.67 - Nasdaq
Cantor Fitzgerald Raises Price Target for CytomX Therapeutics (C - GuruFocus
Cantor Fitzgerald Raises CytomX Therapeutics (NASDAQ:CTMX) Price Target to $10.00 - MarketBeat
CTMX: Barclays Analyst Raises Price Target to $10.00 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Present at Upcoming February Conferences - 富途牛牛
CytomX Therapeutics price target raised to $10 from $8 at Barclays - TipRanks
A Look At CytomX Therapeutics (CTMX) Valuation After Optimistic Analyst Target Hikes On Phase 1 Cancer Data - Sahm
CytomX Therapeutics stock hits 52-week high at 6.16 USD By Investing.com - Investing.com Nigeria
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
CytomX Therapeutics stock hits 52-week high at 6.16 USD - Investing.com
CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: UnitedHealth (UNH), CytomX Therapeutics (CTMX) and Beta Bionics, Inc. (BBNX) - The Globe and Mail
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Insider Monkey
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):